Trial Profile

A Phase 3 study of batoclimab in generalized myasthenia gravis in Japan

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 07 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Batoclimab (Primary)
Indications Myasthenia gravis
Focus Registrational; Therapeutic Use
Sponsors HanAll Biopharma

Most Recent Events

30 Apr 2024 According to a HanAll Biopharma media release, the company expect to initiate this trial in the Second quarter of 2024.
21 Mar 2024 According to a HanAll Biopharma media release, Clinical trial notification (CTN) was approved to initiate a Phase 3 clinical study of batoclimab in thyroid eye disease (TED) in Japan.
26 Oct 2023 Status changed from planning to recruiting as per HanAll Biopharma media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com